Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.51 |
| ▸ | NAAA | Q02083 | 2/20 | 0.50 |
| ▸ | MIF | P14174 | 4/20 | 0.48 |
| ▸ | BACH1 | O14867 | 1/20 | 0.48 |
| ▸ | MAFK | O60675 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938891 | 0.98 | ALDH1A1 (0.96) | ALDH1A1LMNATP53KEAP1NFE2L2 | |
| SCHEMBL14933788 | 0.98 | ALDH1A1 (0.96) | ALDH1A1LMNATP53KEAP1NFE2L2 | |
| SCHEMBL21616875 | 0.98 | ALDH1A1 (0.96) | ALDH1A1LMNATP53KEAP1NFE2L2 | |
| SCHEMBL14797843 | 0.98 | ALDH1A1 (0.96) | ALDH1A1LMNATP53KEAP1NFE2L2 | |
| SCHEMBL21616877 | 0.98 | ALDH1A1 (0.96) | ALDH1A1LMNATP53KEAP1NFE2L2 | |
| SCHEMBL25332003 | 0.98 | ALDH1A1 (0.96) | ALDH1A1LMNATP53KEAP1NFE2L2 | |
| SCHEMBL1688838 | 0.93 | ALDH1A1 (0.88) | ALDH1A1LMNATP53KEAP1NFE2L2 | |
| SCHEMBL18225463 | 0.84 | — | — | |
| SCHEMBL21616871 | 0.79 | ALDH1A1 (0.66) | ALDH1A1LMNATP53KEAP1NFE2L2 | |
| SCHEMBL7560077 | 0.78 | ALDH1A1 (0.64) | ALDH1A1LMNATP53KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106496086-B | The synthetic method of 4- methylsulfonyl butyl isothiocyanates | 沈阳药科大学 | 2018-11-06 | — | — | CN | claimed |
| CN-106496086-A | The synthetic method of 4 methylsulfonyl butyl isothiocyanates | 沈阳药科大学 | 2017-03-15 | — | — | CN | claimed |
| US-8420626-B2 | Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2013-04-16 | — | — | US | claimed |
| US-20100260737-A1 | COMBINATION BETWEEN AN ISOTHIOCYANATE AND LEVODOPA FOR PARKINSON'S DISEASE TREATMENT | ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA (IT) | 2010-10-14 | — | — | US | claimed |
| EP-2229166-A1 | COMBINATION BETWEEN AN ISOTHIOCYANATE AND LEVODOPA FOR PARKINSON'S DISEASE TREATMENT | Alma Mater Studiorum - Università di Bologna (IT) | 2010-09-22 | — | — | EP | claimed |
| EP-2163238-A2 | Compound for lightening skin tone comprising sulforaphane or sulforaphene or their derivates | Henkel AG & Co. KGaA (DE) | 2010-03-17 | — | — | EP | claimed |
| WO-2009083871-A1 | COMBINATION BETWEEN AN ISOTHIOCYANATE AND LEVODOPA FOR PARKINSON'S DISEASE TREATMENT | ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA (IT) | 2009-07-09 | — | — | WO | claimed |
| US-12599640-B2 | Lactobacillus plantarum ZUST49 and bacterial agent, and use thereof | ZHEJIANG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2026-04-14 | — | — | US | disclosed |
| WO-2025069039-A1 | AN IN SITU PROCESS FOR THE PREPARATION OF PRIMARY AMINE COMPOUNDS | SAMANT RAJARAM (IN) | 2025-04-03 | — | — | WO | disclosed |
| US-20250066293-A1 | OIL-BASED ISOTHIOCYANATE PRODUCTS AND PROCESSES FOR PREPARING OIL-BASED ISOTHIOCYANATE PRODUCTS | BRASSICA PROTECTION PRODUCTS LLC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20240374661-A1 | LACTOBACILLUS PLANTARUM ZUST49 AND BACTERIAL AGENT, AND USE THEREOF | ZHEJIANG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-11-14 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| CN-118291309-A | Composite microbial preparation and application thereof | 浙江科技大学 | 2024-07-05 | — | — | CN | disclosed |
| EP-1553933-A1 | MEDICINE COMPRISING A THIOUREA FOR USE AS DEPIGMENTING AGENT OR ANTI-MUTAGENIC AND ANTI-CARCINOGENIC AGENT | LMD (FR) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004032912-A1 | MEDICINE COMPRISING A THIOUREA FOR USE AS DEPIGMENTING AGENT OR ANTI-MUTAGENIC AND ANTI-CARCINOGENIC AGENT | LMD (FR) | 2004-04-22 | — | — | WO | disclosed |
| US-RE36784-E | Chemoprotective isothiocyanates | THE JOHNS HOPKINS UNIVERSITY (US) | 2000-07-18 | — | — | US | disclosed |
| US-5589504-A | Treatment of newborn jaundice | CORNELL RESEARCH FOUNDATION, INC. (US) | 1996-12-31 | — | — | US | disclosed |
| US-5411986-A | Chemoprotective isothiocyanates | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-05-02 | — | — | US | disclosed |
| WO-1994019948-A9 | CHEMOPROTECTIVE ISOTHIOCYANATES | — | 1994-11-10 | — | — | WO | disclosed |
| WO-1994019948-A1 | CHEMOPROTECTIVE ISOTHIOCYANATES | CHO CHEON GYU (US) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599640-B2 | Lactobacillus plantarum ZUST49 and bacterial agent, and use thereof | ZDHHC9, GCLC, SI | ALDH1A1 3275/4885LMNA 3811/4885TP53 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.